tradingkey.logo

Instil Bio Announces US FDA Clearance Of Investigational New Drug (Ind) Application For Axn-2510

ReutersJul 2, 2025 10:57 AM

- Instil Bio Inc TIL.O:

  • INSTIL BIO ANNOUNCES U.S. F.D.A. CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR AXN-2510, A PD-L1XVEGF BISPECIFIC ANTIBODY, FOR A PHASE 1 TRIAL IN RELAPSED/REFRACTORY SOLID TUMORS

  • INSTIL BIO INC - TO INITIATE PHASE 1 TRIAL OF '2510 BEFORE END OF 2025

  • INSTIL BIO INC - INITIAL SAFETY AND EFFICACY RESULTS FROM PHASE 2 STUDY EXPECTED IN H2 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI